邢述 - 吉林大学 - 生命科学学院

个人简介

教育经历： 2003.9~2008.12 吉林大学生命科学院博士研究生 2000.9~2003.6 吉林大学生命科学院硕士研究生 1996.9~2000.6 吉林大学生命科学院本科生工作经历： 2016.09 ~现在吉林大学生命科学学院教授 2010.09~2016.09 吉林大学生命科学学院副教授 2003.07~2010.09 吉林大学生命科学学院助教、讲师 2005.08~2008.09 美国俄克拉荷马大学健康科学中心访问学者 2005.02~2005.07 美国范德比尔特大学医学中心研究成果：首次发现真性红细胞增多症患者体内存在蛋白质酪氨酸激酶JAK2V617F突变，最先应用JAK2V617F转基因小鼠模型证明了JAK2V617F是导致骨髓增殖性肿瘤的原因。以蛋白质酪氨酸激酶和磷酸酶为靶标，先后从中草药、有机和无机金属配合物中筛选到20余种极具临床应用前景的治疗2型糖尿病、癌症、免疫缺陷等人类重大疾病的抑制剂。近年来，申请人先后主持和参与科研课题10余项，发表SCI收录的论文37篇，以第一作者和通讯作者身份发表的论文12篇，获得吉林省自然科学奖一等奖1次（2015年，第二完成人）、吉林省科技进步奖一等奖1次（2010，第三完成人）、中华医学科技奖三等奖1次（2014年，第二完成人）。

研究领域

1、蛋白质酪氨酸激酶和磷酸酶与重大疾病相关性的研究。 2、蛋白质酪氨酸激酶和磷酸酶抑制剂的筛选。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Sui Y, Fu X, Wang Y, Hu W, Zhang T, Liu W, Jiang L, Xing S*, Fu X*. Xu X*. Expression, purification and characterization of a catalytic domain of human protein tyrosine phosphatase non-receptor 12 (PTPN12) in Escherichia coli with FKBP-type PPIase as a chaperon. Protein Expr Purif. 2018, 142: 45-52. Epub 2017 Sep 28 2.Jia Y, Lu L*, Zhu M*, Yuan C, Xing S*, Fu X. A dioxidovanadium (V) complex of NNO-donor Schiff base as a selective inhibitor of protein tyrosine phosphatase 1B: Synthesis, characterization, and biological activities. Eur J Med Chem. 2017, 128:287-292. 3.Li Y，Yuan C，Lu L*，Zhu M，Fu X，Xing S*，Gao Z. Synthesis, Crystal Structure and Protein Tyrosine Phosphatase Inhibition of a Copper(II) Complex with N-(2-Pyridylmethyl)-L-serine, Chem J Chinese U. 2016, 12: 2138-43. 4.Sun J, Wang Y, Fu X, Chen Y, Wang D, Li W, Xing S*, Li G*. Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice. Biomed Res Int. 2015; 2015:139451. doi: 10.1155/2015/139451. 5.Ren X, Wang C, Wu L, Li H, Chi L, Sun L, Wang B, Cui H, Angiolini L, Bianchi A, Caccia P, Xing S*, Fu X*, Zhang J*. Bioactivity assay of porcine relaxin based on cAMP accumulation in THP-1 cells quantified by LC-MS/MS. J Pharm Biomed Anal. 2015, 111: 320-3. 6.Li J, Liu X, Chu H, Fu X, Li T, Hu L*, Xing S*, Li G*, Gu J, Zhao ZJ. Specific dephosphorylation of janus kinase 2 by protein tyrosine phosphatases. Proteomics. 2015, 15(1): 68-76. 7.Zhu R, Lu L*, Zhu M*, Han H, Yuan C, Xing S*, Fu X. Synthesis and evaluation of copper complexes of Schiff-base condensates from 5-substituted-2-hydroxybenzaldehyde and 2-substituted-benzenamine as selective inhibitors of protein tyrosine phosphatases. Inorg Chim Acta. 2013, 405: 91-7. 8.Han H, Lu L*, Wang Q, Zhu M*, Yuan C, Xing S*, Fu X. Synthesis and evaluation of xovanadium (iv) complexes of Schiff-base condensates from 5-substituted-2-hydroxy benzaldehyde and 2-substituted-benzenamine as selective inhibitors of protein tyrosine phosphatase 1B. Dalton Trans. 2012, 41: 11116-24. 9.Lu L, Gao X, Zhu M*, Wang S, Wu Q, Xing S*, Fu X, Liu Z, Guo M*. Exploration of biguanido-oxovanadium complexes as potent and selective inhibitors of protein tyrosine phosphatases. Biometals. 2012, 25(3): 599-610.? 10.Ma J, Li Z, Xing S, Ho WT, Fu X, Zhao ZJ. Tea contains potent inhibitors of tyrosine phosphatase PTP1B. Biochem Biophys Res Commun. 2011, 407(1): 98-102. 11.Zhao W, Gao R, Lee J, Xing S, Ho WT, Fu X, Li S, Zhao ZJ. Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011, 4: 4. 12.Xing S, Ho WT, Zhao W, Ma J, Wang S, Xu X, Li Q, Fu X, Xu M, Zhao ZJ. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008, 111(10): 5109-17. 13.Li Z, Xing S, Wang S, Ho WT, Zhao ZJ. Characterization of a highly effective protein substrate for analysis of JAK2 (V617F) activity. Exp Hematol., 2007 Nov; 35(11): 1624-32. 14.Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007, 282(6): 3428-32. 15.Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, Fu X, Zhao ZJ. JAK2(V617F): prevalence in a large Chinese hospital population. Blood. 2007, 109(1): 339-42. 16.Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005, 280(24): 22788-92.